Eli Lilly & Co. Inc. LLY, +0.61% said its new Type 2 diabetes treatment Mounjaro brought in $187.3 million in sales in the third quarter of the year, beating the FactSet consensus of $79.0 million. It was the therapy’s first full quarter on the U.S. market after receiving approval from the Food and Drug Administration in May. Lilly plans to seek FDA approval for a second indication of the drug as a treatment for people with obesity or overweight next year. The company’s stock is up 31.1% this year, while the broader S&P 500 SPX, -0.75% has declined 18.7%.
